

HOWARD P. TAY, M.D., F.A.C.S.

Curriculum Vitae

Signature/ Date

OFFICE LOCATIONS:

Canyon State Urology, P.C.
Division of
Arizona Urology Specialists
5750 W. Thunderbird Road
Suite B-200
Glendale, AZ 85306

Canyon State Urology, P.C.
5757 West Thunderbird Road
Suite E456
Glendale, AZ 85306

HOPE Research Institute
3120 E. Union Hills Drive
Phoenix, AZ 85050
Phone (602) 288-4673
Fax (602) 288-4678
Website: www.hriaz.com

EDUCATION:

- 1992 – 1996 University of California, San Diego Medical Center
San Diego, California
Urology Residency Training (PGY 3-6)
- 1990 – 1992 University of California, San Diego Medical Center
San Diego, California
General Surgery Internship & Residency (PGY 1-2)
- 1986 – 1990 George Washington University
Washington, D.C.
Doctorate of Medicine
- 1982 – 1985 University of California, Berkeley
Berkeley, California
Bachelor of Arts – Medical Physics

CERTIFICATIONS & LICENSURE:

- State Medical Licensure, California (inactive)
State Medical Licensure, Arizona (active)
Drug Enforcement Agency 223 (active)
- 1991 Certified Diplomat of National Board of Medical Examiners
- 1992 Laparoscopy certification – Cedar Sinai Medical Center
- 1994 Microsurgery certification – San Diego Microsurgical Institute and Training Center
- 1996 ESWL certification – Mercy Medical Center
- 1996 Ureteroscopy and Holmium laser certification
- 1996 BARD collagen injection certification
- 1997 Transurethral needle ablation of prostate (TUNA) Certification
- 1997 Microwave therapy of prostate (Prostatron) certification
- 1998 Diplomate of American Board of Urology
- 1998 Prostate cancer brachytherapy certification

HOWARD P. TAY, M.D., F.A.C.S.

Curriculum Vitae

CERTIFICATIONS & LICENSES (continued):

| | |
|------|---|
| 2002 | Neuromodulation implant for urinary urgency and frequency (Interstim) certification |
| 2002 | Prostate and renal cancer cryotherapy (Endocare and Galil) Certification |
| 2004 | Green Light laser prostatectomy certification |
| 2006 | Robotic-assisted surgery certification by Intuitive Surgical System |

PROFESSIONAL SOCIETIES & MEMBERSHIPS:

American Medical Association
William Beaumont Medical Society
Society for the Study of Male Reproduction
American College of Surgeon-Fellowship of American College of Surgeons
American Urological Association-Active Member
Arizona Medical Association
Arizona Urological Association-Active Member
Arizona Chapter of American College of Surgeon
Maricopa County Medical Society
Phoenix Urological Society
Western section of American Urological Association-Active Member

LANGUAGES:

Proficient in Cantonese

HOSPITAL PRIVILEGES:

Banner Thunderbird Hospital (current)
Arrowhead Hospital (current)
Scottsdale Shea Hospital (current)
Scottsdale Thompson Peak Hospital (current)

PROFESSIONAL EXPERIENCE:

| | |
|----------------|--|
| 1998 – present | Adjunct Assistant Professor in Urology, Midwestern University Arizona College of Osteopathic Medicine, Glendale, AZ |
| 1999 – present | President of Canyon State Urology, P.C., Glendale, AZ |
| 1999 – 2001 | Head of laser surgery committee, Thunderbird Samaritan Hospital, Glendale, AZ |
| 2000 – 2002 | Surgery committee representative for Urology, Thunderbird Samaritan Hospital, Glendale, AZ |

HOWARD P. TAY, M.D., F.A.C.S.

Curriculum Vitae

PROFESSIONAL EXPERIENCE (continued):

| | |
|----------------|---|
| 2002 – 2004 | Chief of Surgery, Thunderbird Samaritan Hospital, Glendale, AZ |
| 2002 – 2003 | Executive Committee member-at-large, Thunderbird Samaritan Hospital |
| 2002 – present | Health policy representative for District 8 (Arizona), Western Section of American Urological Association |
| 2002 – 2006 | Member of credentialing committee, Thunderbird Samaritan Hospital, Glendale, AZ |
| 2002 – 2004 | Member of Hospitalist Committee, Thunderbird Samaritan Hospital, Glendale, AZ |
| 2003 – 2008 | Managing Director, Pinnacle Surgery Center, Peoria, AZ |
| 2003 – 2008 | Board of Director, Pinnacle Surgery Center, Peoria, AZ |
| 2003 – 2009 | Board of Director, Maricopa Medical Society |
| 2004 – 2006 | Chair of Bylaws committee, Thunderbird Banner Hospital, Glendale, AZ |
| 2004 – present | Investigator, HOPE Research Institute, Phoenix, AZ |
| 2004 – 2008 | Chair of Membership Committee, Western Section of American Urological Association |
| 2005 – 2008 | Member of Physician Advisory Committee, Thunderbird Banner Hospital, Glendale, AZ |
| 2005 – 2007 | Alternate Board of Director for District 8 (Arizona), Western Section of American Urological Association |
| 2007-2009 | Board of Director for District 8 (Arizona), Western Section of American Urological Association |
| 2008-present | Board of Director, Arizona Urology Specialists (AUS). |
| 2009 | President, Arizona Prostate Cancer Center (APCC) |

AWARDS:

| | |
|-------------|---|
| 1982 | California Association of Chinese-American Academic Scholarship |
| 1982 – 1984 | Levi Strauss Honorary Scholastic Scholarship |
| 1987 | W.T. Gills, Jr. Medical Student Research Fellowship |
| 1994 | Western Section American Urological Association Resident Scholarship |
| 1995 – 1996 | Chairman's Prize for outstanding surgery chief resident, University of California, San Diego Medical Center |
| 2005 | TOP DOC Award for 2005 as mentioned in Phoenix Magazine |
| 2006 | TOP DOC Award for 1st and 2nd quarters of 2006, Thunderbird Banner Hospital |

HOWARD P. TAY, M.D., F.A.C.S.

Curriculum Vitae

PUBLICATIONS:

Harmon, J., Hakki, F., Malthaner, R., Saini, N., and Tay, H.P.: Luminal factors determine the location of cysteamine-induced duodenal ulcers. *Digestive Disease and Science* 1988; 33: 902.

Tay, H.P., Chaparala, R., Harmon, J., Nuesken, H., Saini, N., Hakki, F., and Schweitzer, E.: Bismuth subsalicylate reduces peptic injury of the esophagus in rabbits. *Gut* 1990; 31: 11-16.

Tay, H.P., Bidair, M., Shabaik, A., Gilbaugh, J.H., and Schmidt, J.D.: Primary yolk sac tumor of the prostate in a patient with Klinefelter's Syndrome. *Journal of Urology*, 1995; 153: 1066-1069.

Tay, H.P. and Juma, S.: Magnetic resonance imaging of the Urolume urethral stent. *Journal of Urology*, 1995; 153: 1225-6.

Tay, H.P., Joseph, A., and Juma, S.: Psychogenic impotence in patients with spinal cord injuries. *Archives of Physical Medicine and Rehabilitation*, 1996; 77 (4): 391-3.

Tay, H.P., Parsons, C.L., Stein, P.: Electrophysiologic monitoring of the effects of soluble virulent factor(s) in *E. coli*-infected urine in a rabbit bladder model. *Urology*, 1996; 48 (3):389-392.

PRESENTATIONS:

Extragenital germ cell tumor of the prostate in a patient with Klinefelter's Syndrome, Western Section Meeting of the American Urological Association, Palms Springs, CA, 11/1993

Use of RigiScan monitoring to evaluate erectile function in patients with spinal cord injuries, Western Section Meeting of the American Urological Association, Seattle, WA, 8/1994

Electrophysiologic effects of *E. Coli* soluble virulent factor(s) in a New Zealand rabbit bladder model, Western Section Meeting of the American Urological Association, Seattle, WA, 8/1994

Malignant melanoma presenting as a testicular mass (Presented by Biren Patel, M.D.), Western Section Meeting of the American Urological Association, Phoenix, AZ, 10/1995

Protective effects of bismuth subsalicylate against pepsin-induced reflux esophagitis in a New Zealand rabbit model
William Beaumont Medical Society Research Conference
Washington, D.C., 4/1998

HOWARD P. TAY, M.D., F.A.C.S.

Curriculum Vitae

RESEARCH EXPERIENCE:

Development of computer software/hardware for measuring lipid profiles in serum using photometric scanning., University of California, Department of Biophysics, Berkeley, CA, 1985

Studied the protective effects of bismuth subsalicylate against reflux esophagitis in a New Zealand rabbit model. Analyzed the effects of cysteamine-induced duodenal ulcers in a rat model. Assisted in the development of a stapleless end-to-end intestinal anastomotic device. George Washington University, Veterans Administration Medical Center, Department of Surgery, Washington, D.C., 1987 – 1989

Studied the electrophysiologic effects of E. coli soluble virulent factor(s) in a New Zealand rabbit model., University of California, San Diego Medical Center, Veterans Administration Medical Center Department of Surgery, Division of Urology, San Diego, CA, 1993 – 1994

A Randomized, Double Blind, Parallel group study to investigate the efficacy and safety of treatment with XXX and XXX, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia.

A randomized, double-blind, placebo-controlled, parallel-group, Multicenter study to assess the efficacy and safety of daily oral administration of 5 and 10mg XXX in patients not previously exposed to anticholinergic drugs for the treatment of urgency associated with overactive bladder.

An open-label Multicenter study to assess the efficacy and safety of daily oral administration of 5 and 10 mg XXX in patients who wish to switch from XXX for the treatment of overactive bladder symptoms.

Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 3 Arm, 12-Month Study to Evaluate the effects of GPI 1485 on Erectile Function in Patients undergoing Bilateral Nerve-Sparing Radical Retropubic Prostatectomy for Prostatic Cancer

A randomized, double-blind, placebo-control, multi-center efficacy and safety study of XXX for the prevention of prostate cancer in men with high grade Prostatic Intraepithelial Neoplasia (PIN).

A Double-Blind, Randomized, Placebo-Controlled Trial of XXX for the Treatment of Chronic Non-Bacterial Prostatitis.

A randomized, double blind, placebo and active controlled efficacy and safety study of XXX in patients with overactive bladder or urge urinary incontinence.

A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of XXX in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia.

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center Safety and Efficacy, Phase 4 Study of XXX or Placebo in Combination with XXX for the Treatment of Residual OAB Symptoms of Urgency and Frequency in Men.

A Two-Arm, Open-Label, Randomized, Multi-Center Pharmacokinetic and Long-term Safety Study of Intramuscular Injections of XXX in Hypogonadal Men.

HOWARD P. TAY, M.D., F.A.C.S.

Curriculum Vitae

RESEARCH EXPERIENCE (continued):

Prospective Multi-Center Study to Evaluate the Diagnostic Performance of the XXX for Prostate Cancer Screening.

A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using XXX as a study calibrator, to evaluate efficacy and safety of XXX in women with overactive bladder including urge urinary incontinence

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety XXX 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia in Men with Both Erectile Dysfunction and Benign Prostatic Hyperplasia

A Multi-Center, Double-Blind, Placebo-Controlled Investigation of XXX in the Treatment of Subjects with Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF XXX IN THE TREATMENT OF ERECTILE DYSFUNCTION FOLLOWING BILATERAL NERVE-SPARING RADICAL PROSTATECTOMY